Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial

Chamithra D. Rupasinghe, Theodosios Kantas, Rohail Sani, Natalia M. Avendaño Capriles, Ramil Dadabhoi, Afreenish Gul, Camilo Andrés Avendaño Capriles, Noman Khurshid Ahmed, Sohaib Tousif

Abstract

Introduction: Statin use in secondary prevention after acute coronary syndrome (ACS) can play an important role in enhancing clinical outcomes, this has been proven in several randomized trials. This study was conducted to compare the efficacy of moderate-intensity and high-intensity statins in controlling low-density lipoprotein (LDL) after ACS.

Methodology: A randomized control trial was conducted at the Cardiology Department of Liaquat National Hospital, Karachi, Pakistan, from July 2020 to September 2021. During admission, patients were either started on a high-intensity statin dose (rosuvastatin 20 mg) or moderate-intensity statin (rosuvastatin 10 mg) by a computer-generated allocation sequence. Patients were followed-up in the outpatient department (OPD) after 3 months, and a lipid profile at follow-up was obtained. The percentage of LDL change was determined on 3 months of follow-up.

Results: A total of 590 patients were enrolled in the study. Out of all participants enrolled, 534 (80.48%) completed the 3-month follow-up. The mean age of participants was 58.08 (+12.06) years. High-intensity statin therapy is positively associated with positive LDL change (adjusted odds ratio [AOR]=4.45, P-value=0.001).

Conclusion: Our data implies that high-intensity statin medication may be an initial therapeutic option to decrease LDL. However, future randomized clinical trials should corroborate these findings.

Introduc
effects of high-intensity statins are due to the statin intensity itself or the lower levels of LDL-C achieved by high-intensity statins compared to moderate-intensity statins. In Pakistan, no study compared the efficacy of moderate-intensity and high-intensity statin in controlling LDL. Thus, this study was conducted to compare the efficacy of moderate-intensity and high-intensity statins in controlling LDL after ACS.

**Materials And Methods**

**Study design:** A randomized control trial was conducted at the Cardiology Department of Liaquat National Hospital, Karachi, Pakistan, from July 2020 to September 2021.

Inclusion criteria: All patients aged 25 to 85 years admitted with acute ACS (either new onset or having another episode) were enrolled in the study and whose lipid profile samples were obtained within 24 hours of the onset of the ACS.

Exclusion criteria: Patients were excluded if they were contraindicated to rosuvastatin such as hypersensitivity reactions including rash, pruritus, urticaria, and angioedema or who developed serious adverse effects of rosuvastatin (rhabdomyolysis with and acute renal failure, myopathy, liver enzyme abnormalities) that was assessed using laboratory and clinical findings and previous history. Patients with acute liver disease were also excluded (assessed by persistent elevations of hepatic transaminase levels). Pregnant and lactating women and patients who were already on statin therapy were also excluded from the study.

Ethical approval for this study was obtained from the institutional review board of Liaquat University Hospital (IRB Number: LUH_2020_06_05).

**Sample size and sampling technique**

The sample size was calculated considering the proportion of patients achieving LDL-C level of ≤100 mg/dL, i.e., 71% [14], 95% CI, design precision of 5%, and lost to follow-up 20%. The total sample size calculated was 590: 295 in high-intensity statin and 295 in medium-intensity statin therapy. Participants were enrolled using a non-probability consecutive sampling technique.

**Data collection**

After enrollment, patients’ baseline data was collected through chart review in-hospital and patient interviews. We recorded age, gender, BMI, diagnosis, prior cardiovascular history, other comorbidities, smoking status, and diagnosis. According to the guidelines, there are no precise LDL-C cut-offs for commencing statin therapy in individuals aged greater and lesser than 75 years. A class-I recommendation is that all ACS patients begin statin medication, irrespective of their baseline LDL-C level [15]. The ultimate goal is to reduce LDL-C of greater than or equal to 50% from their untreated baseline [16]. We categorized the patients into two groups, including positive (if they achieved a reduction in LDL-C of greater than or equal to 50%) and negative (if they did not achieve a reduction in LDL-C of greater than or equal to 50%) [15].

During admission, patients were either started on a high-intensity statin dose (rosuvastatin 20 mg) or moderate-intensity statin (rosuvastatin 10 mg) by a computer-generated allocation sequence. During their stay in the hospital, patients were clinically monitored for the development of an allergic reaction upon initiation of rosuvastatin. Baseline liver function tests were also obtained during admission. For standardization, all patients had prescribed a single brand of rosuvastatin. On discharge from the hospital, patients and their attendants were educated about the medicine, dose, and side effects.

Compliance with medication was assessed by providing patients with a dose chart to fill in every day after taking medicines. Non-compliant patients are those who have not taken a statin for more than 7 days in a month (consecutively or sporadically). Patients with whom contact has not been established after 3 months were considered unfollowed. Patients who were lost to follow-up or did not adhere to medications were excluded from the final analysis. Patients were followed-up in the outpatient department (OPD) after 3 months, and a lipid profile at follow-up was obtained. The percentage of LDL change was determined on 3 months of follow-up.

**Statistical analysis**

We treated analysis as intent-to-treat: patients not adhering to treatment and permanently lost to follow-up were excluded. Baseline characteristics of patients were presented as percentages for categorical variables and mean for continuous variables. Two groups (medium-intensity and high-intensity statin) were compared using the chi-square test and t-test for categorical and continuous variables, respectively. To assess the impact of statin therapy on LDL change, multivariable logistic regression was used. P-value <0.05 was considered significant.

**Results**
A total of 590 patients were enrolled in the study. Of all participants enrolled, 150 (25.42%) were unadhered to statin therapy, and 116 (19.66%) were lost to follow-up. The remaining 334 (80.48%) completed the 3-months follow-up, including 138 in the high-intensity statin group and 196 in the moderate-intensity statin group.

The mean age of participants was 58.08 (+12.06) years, the majority of participants were male (71.26%), 83.83% of participants had at least one comorbidity. Of all participants who completed a 3-month follow-up, 58.58% were adherent to statin therapy, as shown in Table 1. The most common morbidity found among participants included hypertension (72.86%), previous history of coronary artery disease (64.29%), and diabetes (56.43%), as shown in Table 2. Table 3 shows the characteristics of participants categorized based on study groups. No significant difference was found between the two groups in terms of baseline characteristics of participants (P-value>0.05).

| Variable     | Categories             | n(%)          |
|--------------|------------------------|---------------|
| Age*         | 58.08 (+12.06)         |               |
| Gender       | Male                   | 238 (71.26)   |
|              | Female                 | 96 (28.74)    |
|              | No                     | 54 (16.17)    |
| Comorbidity  | Yes                    | 280 (83.83)   |
|              | Underweight            | 20 (5.99)     |
|              | Normal                 | 110 (32.93)   |
|              | Overweight             | 133 (39.82)   |
|              | Obese                  | 71 (21.26)    |
| Group        | Moderate-intensity statin | 196 (58.68) |
|              | High-intensity statin  | 138 (41.32)   |
| Smoking status| Current smoker         | 44 (13.17)    |
|              | Ex-smoker              | 20 (5.99)     |
|              | Never smoker           | 270 (80.84)   |
| Diagnosis    | STEMI                  | 214 (64.07)   |
|              | Non-stable angina      | 94 (28.14)    |
|              | NSTEMI                 | 26 (7.78)     |

**TABLE 1: Baseline characteristics of participants**

*Mean (Standard deviation)

BMI: body mass index; NSTEMI: non-ST-elevation myocardial infarction; STEMI: ST-elevation myocardial infarction
### Table 2: List of comorbidities among study participants

| Comorbidity                  | n (%)     |
|------------------------------|-----------|
| Diabetes mellitus            | 158 (56.43) |
| Hypertension                 | 204 (72.86) |
| Prior coronary artery disease| 180 (64.29) |
| Prior PCI                    | 84 (30.00)  |
| Prior heart failure          | 74 (26.43)  |
| Prior stroke                 | 28 (10.00)  |
| Hepatitis or CLD             | 8 (2.86)    |
| CKD                          | 50 (17.86)  |
| Others                       | 26 (7.78)   |

PCI: percutaneous coronary intervention; CLD: chronic liver disease; CKD: chronic kidney disease

### Table 3: Baseline characteristics categorized on the basis of study groups

| Variable       | Categories     | Moderate-Intensity Statin n(%) | High-Intensity Statin n(%) | P-value |
|----------------|----------------|-------------------------------|---------------------------|---------|
| Age*           |                | 58.79 (11.45)                | 57.08 (12.84)             | 0.104   |
| Gender         | Male           | 136 (69.39)                  | 102 (73.91)               | 0.368   |
|                | Female         | 60 (30.61)                   | 36 (26.09)                |         |
| Comorbidity    | No             | 26 (13.27)                   | 28 (20.29)                | 0.086   |
|                | Yes            | 170 (86.73)                  | 110 (79.71)               |         |
| BMI            | Underweight    | 8 (4.08)                     | 12 (8.70)                 |         |
|                | Normal         | 64 (32.65)                   | 46 (33.33)                | 0.263   |
|                | Overweight     | 78 (39.80)                   | 55 (39.86)                |         |
|                | Obese          | 46 (23.47)                   | 25 (18.12)                |         |
| Smoking Status | Current smoker | 20 (10.20)                   | 24 (17.39)                |         |
|                | Ex-smoker      | 12 (6.12)                    | 8 (5.80)                  | 0.161   |
|                | Never smoker   | 164 (83.87)                  | 106 (76.81)               |         |
| Diagnosis      | STEMI          | 126 (64.29)                  | 88 (63.77)                |         |
|                | Non-stable angina | 56 (28.57)       | 38 (27.54)                | 0.867   |
|                | NSTEMI         | 14 (7.14)                    | 12 (8.70)                 |         |

*Mean (Standard deviation)
NSTEMI: Non-ST-elevation myocardial infarction; STEMI: ST-elevation myocardial infarction

### Impact of statin therapy

First, a univariate analysis was done using the chi-square test of independence to assess the impact of high-intensity statin therapy on LDL change. Table 4 shows that the statin therapy is significantly associated with LDL change (P-value=0.001). Other variables significantly associated with positive LDL change included age of participant (P-value=0.001), comorbidity (P-value=0.002), smoking status (P-value=0.045), and diagnosis (P-value=0.004). Variables significantly associated with positive LDL change were included in the final model.
developed using multivariable logistic regression. The final model was composed of four independent variables and an outcome variable.

| Variable        | Categories       | Negative LDL Change | Positive LDL Change | P-value |
|-----------------|------------------|---------------------|---------------------|---------|
| Age*            | 59.82 (11.97)    | 54.13 (11.35)       | 0.001*              |
| Gender          | Male             | 166 (71.55)         | 72 (70.59)          | 0.858   |
|                 | Female           | 66 (28.45)          | 30 (29.41)          |         |
| Comorbidity     | No               | 28 (12.07)          | 26 (25.49)          | 0.002*  |
|                 | Yes              | 204 (87.93)         | 76 (74.51)          |         |
| BMI             | Underweight      | 14 (6.03)           | 6 (5.88)            |         |
|                 | Normal           | 76 (32.76)          | 34 (33.33)          | 0.966   |
|                 | Obese            | 51 (21.98)          | 20 (19.61)          |         |
|                 | Overweight       | 91 (39.22)          | 42 (41.18)          |         |
| Group           | High-intensity   | 161 (69.40)         | 35 (34.31)          | 0.001*  |
|                 | Low-intensity    | 71 (30.60)          | 67 (65.69)          |         |
| Smoking Status  | Current smoker   | 26 (11.21)          | 18 (17.65)          | 0.045*  |
|                 | Ex-smoker        | 18 (7.76)           | 2 (1.96)            |         |
|                 | Never smoker     | 188 (81.03)         | 82 (80.39)          |         |
| Diagnosis       | STEMI            | 149 (64.22)         | 65 (63.73)          |         |
|                 | Non-stable angina| 72 (31.03)          | 22 (21.57)          | 0.004*  |
|                 | NSTEMI           | 11 (4.74)           | 15 (14.71)          |         |

**TABLE 4: Univariate analysis of factors associated with LDL change**

*Factors significant at P-value<0.25  
*Mean (Standard deviation)  
LDL: low-density lipoprotein; NSTEMI: non-ST-elevation myocardial infarction; STEMI: ST-elevation myocardial infarction

Table 5 shows the impact of high-intensity statin therapy on LDL change after adjusting with other independent variables. High-intensity statin therapy is positively associated with positive LDL change (adjusted odds ratio [AOR]=4.45, P-value=0.001). Increased age is negatively associated with positive LDL change (AOR=0.96, P-value=0.005). In addition, the odds of positive LDL change are 53% lower among patients with at least one comorbidity than patients without any comorbidity (AOR=0.47, P-value=0.031). Last, patients diagnosed with NSTEMI have higher odds of positive LDL change than patients diagnosed with STEMI (AOR=3.32, P-value=0.022).
| Variable     | Categories          | AOR   | 95% CI      | P-value |
|--------------|---------------------|-------|-------------|---------|
| Group        | High-intensity statin | Reference                  |          |         |
|              | Moderate-intensity statin | 4.45  | 2.63-7.55   | 0.001   |
| Age          |                     | 0.96  | 0.94-0.99   | 0.005   |
| Comorbidity  | No                  | Reference                  |          |         |
|              | Yes                 | 0.47  | 0.24-0.93   | 0.031   |
|              | STEMI               | Reference                  |          |         |
| Diagnosis    | Non-stable angina   | 1.48  | 0.78-2.49   | 0.225   |
|              | NSTE MI             | 3.32  | 1.18-9.29   | 0.022   |

**TABLE 5: Impact of high-statin therapy on LDL change (multivariable logistic regression)**

LDL: low-density lipoprotein; AOR: adjusted odds ratio; CI: confidence interval; NSTEMI: non-ST-elevation myocardial infarction; STEMI: ST-elevation myocardial infarction

**Discussion**

In the current study on 334 patients with ACS, patients who received high-intensity statin had better LDL change than patients who received moderate-intensity statin. In previous studies, higher-intensity statin therapy showed better clinical outcomes than moderate-intensity statin therapy, but these studies particularly focused on the Western population [17-18]. As per the 2013 ACC or AHA guidelines, high-intensity statins need to be used for all patients with deemphasized targeting specific LDL-C levels and atherosclerotic cardiovascular disease (ASCVD) [16].

In previous randomized trials, statin medication with an absolute reduction in LDL-C showed consistent prognostic effects for primary and secondary prevention [2-3]. Additionally, the experimental and clinical data demonstrated the pleiotropic impacts of statins like antithrombotic activity, oxidative stress reduction, endothelial function enhancement, and anti-inflammatory activity [19].

After adjusting for potential confounding variables in the current study, high-intensity statin therapy provided incremental benefits over moderate-intensity statin therapy in patients with the ACS. In individuals with established CAD, a recently accepted guideline recommends using high-intensity statin treatment [16]. However, Asian patients have distinct clinical and genetic backgrounds than Westerners, so this advice may not be immediately applicable to them. A pharmacokinetic study also showed that statins have a more significant effect in East Asian patients than in Western patients, related to differences in statin pharmacokinetics [20]. The current study showed different findings than previous studies that did not find any significant differences between lower- and moderate-statin therapy related to clinical outcomes.

Stronger statins may be helpful in high-risk East Asian individuals, such as those with left main disease, multi-vessel disease, or diabetes [20]. According to current guidelines, stronger statins with target LDL cholesterol levels of 70 mg/dL or a 50% reduction if the baseline LDL cholesterol is between 70 and 135 mg/dL would be more appropriate in these patients [21]. Thus, even in Asian people, high-statin therapy could be useful in high-risk patients.

The benefits of high-intensity statin therapy are visible in the current study regarding reduction of LDL. Only after 8 to 12 months of treatment, the JAPAN-ACS research find that statin therapy significantly reduces coronary atherosclerosis [22]. According to a recent meta-analysis, high-intensity statin therapy does not result in plaque regression in ACS patients during the first 5 months; nevertheless, plaque regression occurs after 6–12 months and lasts for more than 12 months [23]. When comparing studies using high-intensity statin treatment to trials using moderate-statin treatment, subgroup analysis demonstrated more dramatic decreases in LDL-C and major adverse cardiovascular events (MACE) risk in the high-intensity statin group [24]. A personalized treatment strategy with high-dose statins has been proven to be more effective than LDL-C-based target approaches in preventing coronary heart disease events [25].

The current study has certain limitations. First, the study was conducted at only one center in Karachi; therefore, the findings of this study should be confirmed in other prospective clinical trials with long-term clinical follow-ups. Second, the current study included a population in Pakistan only; thus, it might not be possible to generalize our findings to other regions. Considering the current study results, it is important to carry out future studies in larger sample size and involve more study sites to assess whether high-statin...
therapy is effective enough to promote positive clinical outcomes.

Conclusions
In the current study, the efficacy of high-intensity statin therapy was compared with moderate-intensity statin therapy among patients with ACS. LDL management is one of the important components of cardiac disease management and thus considering the benefits of high-intensity statin in reducing LDL levels among patients with ACS, high-intensity statin medication may be an initial therapeutic option to decrease LDL. However, future randomized clinical trials should corroborate these findings.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board of Liaquat University Hospital issued approval LUH_2020_06_05. All documents related to the study were reviewed and the study has been approved. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998, 279:1615-22.
2. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344:1383-9.
3. Stone NJ, Robinson JG, Lichtenstein AH, et al.: ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014, 129:546-8.
4. Catapano AL, Graham I, De Backer G, et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Atherosclerosis. 2016, 253:281-344. 10.1016/j.atherosclerosis.2016.08.018
5. Dai W, Huang XS, Zhao SP: No evidence to support high-intensity statin in Chinese patients with coronary heart disease. Int J Cardiol. 2016, 204:57-8. 10.1016/j.ijcard.2015.11.164
6. Zhao SP, Yu BL, Peng DQ, Hoo Y: The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. Atherosclerosis. 2014, 235:707-12. 10.1016/j.atherosclerosis.2015.12.005
7. Lee E, Ryan S, Birmingham B, et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005, 78:350-41. 10.1016/j.clpt.2005.06.013
8. Birmingham BK, Bujar SR, Ebsly R, et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015, 71:329-40. 10.1007/s00228-014-1800-0
9. Park MW, Park GM, Han S, et al.: Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: a propensity-score matching analysis. PLoS One. 2018, 13:e0207889. 10.1371/journal.pone.0207889
10. Natsuki M, Furukawa Y, Morimoto T, et al.: Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. Cir J. 2012, 76:1369-79. 10.1255/cirj.11-1356
11. Yeh YT, Yin WH, Tserng WK, et al.: Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? – Data from a multicenter registry cohort study in Taiwan. PLoS One. 2017, 12:e0186661. 10.1371/journal.pone.0186661
12. Cannon CP, Braunwald E, McCabe CH: Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myoccardial infarction 22 investigators: intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350:1495-504. 10.1056/NEJMoa04058
13. Robinson JG, Stone NJ: The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J. 2015, 14:2110-4. 10.1093/eurheartj/ehv182
14. Melloni C, Shah BR, Ou FS, et al.: Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications Applied aNd SuTainEd Over Time (MAINTAIN) registry. Am Heart J. 2010, 160:1121-9, 1129.e1. 10.1016/j.ahj.2010.09.008
15. Chou R, Dana T, Blazina I, Daegen M, Bougatsos C, Grusding S, Jeanne TL: Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force [Internet].
16. Stone NJ, Robinson JG, Lichtenstein AH, et al.: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014, 63:2889-934. 10.1016/j.jacc.2013.11.002
17. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005, 352:1425-35. 10.1056/NEJMoa050461
18. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350:1495-504. 10.1056/NEJMoa040583
19. Miyachi K, Daida H: Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease: LDL-cholesterol: the lower, the better; is it true for Asians? (Pro). Circ J. 2010, 74:1718-50. 10.1253/circj.74.1718
20. Sakamoto T, Ogawa H: ‘Just make it lower’ is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con). Circ J. 2010, 74:1731-41. 10.1253/circj.74.1731
21. Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH: Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation. 2007, 115:1363-70. 10.1161/CIRCULATIONAHA.106.645473
22. Hiro T, Kimura T, Morimoto T, et al.: Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009, 54:295-302. 10.1016/j.jacc.2009.04.032
23. Tang X, Yang Y, Luo S, et al.: The effect of statin therapy on plaque regression following acute coronary syndrome: a meta-analysis of prospective trials. Coron Artery Dis. 2016, 27:636-49. 10.1097/MCA.0000000000000403
24. Giugliano RP, Mach F, Zavitz K, et al.: Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017, 377:633-43. 10.1056/NEJMoa1701131
25. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S: Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010, 152:69-77. 10.7326/0003-4819-152-2-201001190-00004